EyePoint Pharmaceuticals Announces Strategic Shift to DURAVYU DME Following Phase III Wet AMD Trial Failures
EyePoint Pharmaceuticals (EYPT) management expressed deep disappointment following the announcement that its two Phase III clinical trials for wet Age-Related Macular Degeneration (wet AMD) failed to meet their primary endpoints in the full analysis population. The failure of these trials represents a significant setback for the company's previous development trajectory. In response, the company is pivoting its strategic focus toward DURAVYU for the treatment of Diabetic Macular Edema (DME). Management expects top-line data from the COMO and CAPRI clinical trials to be released in early Q4 2027. This shift marks a critical transition in the company's pipeline as it seeks new pathways for commercial viability.
Tickers: $EYPT
Topics: clinical trial failure earnings call Phase III trials wet AMD
Read the full article at Seeking Alpha
Part of the story EyePoint, Inc. - 8-K Filing (4 articles)